Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
High Content Assay to Identify Modulators of Dengue Virus Infection
Wednesday, 23 November 2011 at 11:15
Add to Calendar ▼2011-11-23 11:15:002011-11-23 12:15:00Europe/LondonHigh Content Assay to Identify Modulators of Dengue Virus InfectionScreening Asia 2011 in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases. Current treatments for DENV infections are nonspecific and largely ineffective. Efforts to identify and repurpose approved drugs will be presented.
Add to Calendar ▼2011-11-22 00:00:002011-11-23 00:00:00Europe/LondonScreening Asia 2011Screening Asia 2011 in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2011-11-23 11:15:002011-11-23 12:15:00Europe/LondonHigh Content Assay to Identify Modulators of Dengue Virus InfectionScreening Asia 2011 in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
